RDHL

Redhill Biopharma Ltd.

0.38 USD
+0.00 (+0.99%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Redhill Biopharma Ltd. stock is down -8.37% since 30 days ago. The next earnings date is Apr 8, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 50% of the previous 11 July’s closed higher than June.

About Redhill Biopharma Ltd.

RedHill Biopharma Ltd. primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain. Its clinical late-stage investigational development programs include RHB-204, which is in Phase 3 study for pulmonary nontuberculous mycobacteria infections.